

Improving prostate cancer outcomes globally: A Movember update

Rebecca Dabbs, Sibilah Breen, Kris Bennett, Jennifer Edgecombe, Kade Roberts, Lauren King, Sam McKeown, Sarah Weller.

Affiliations

Movember Institute of Men's Health, Melbourne, Australia

Background

Movember has invested over AUD \$650M to improve prostate cancer mortality and quality of life, addressing survivorship, active surveillance, disease progression, side effects, and care inequities through global clinical and research collaborations.

Methods

Using collective impact and partnership models that include key opinion leaders, clinicians, researchers and consumers, Movember's current prostate cancer strategy is structured around five global initiatives: sexual health and wellbeing, health equity, personalized cancer care, clinical quality and prostate cancer research (personalized active surveillance; preventing disease progression).

Results

Since 2024, this work has achieved the following major outcomes:

- **Sexual Health & Wellbeing:** Convened 135 sector experts across 6 countries (AU, CA, NZ, UK, US, IR) to embed best-practice sexual health guidelines in routine care and co-design implementation roadmaps. Partnered with International Society of Sexual Medicine and launched free clinician resources and toolkit. Trained >95 providers trained through Sexual Health and Rehabilitation eTraining. Convened global biomedical experts to advance sexual medicine research priorities.
- **Health Equity:** AUD \$6.6M invested across 18 competitive grants in five countries that target disparities in access, outcomes and survivorship for marginalized communities. Projects include navigation, social isolation, early detection, and culturally tailored interventions for Black men.
- **Personalized Cancer Care:** Completed recruitment for IRONMAN EMPRO (Engaging Men in Patient Reported Outcomes) sub-study trial across four countries, which tests PROMs integration in advanced disease. Invested AUD \$2.83M across six new PROMs/PREMs implementation grants (AU, CA, UK). Launched knowledge translation supported through the PRMs in Practice global webinar series.
- **Clinical Quality:** Movember registries expanded to collectively include >315,000 men, with >250,000 PROMs collected across 25 countries, contributing to a global infrastructure that measures outcomes and drives quality improvement. Launched Irish Prostate Cancer Outcomes Registry 2 (IPCOR2) including a biobank. Completed data collection for TrueNTH Global Registry. IRONMAN registry for advanced prostate cancer scheduled to complete recruitment in 2026.
- **Personalized Active Surveillance:** Co-developing an international clinical trial (MEASURED) to test an MRI-led, risk adapted surveillance framework for low- to favorable intermediate-risk disease. International consensus reached on study protocol. 25+ clinical sites engaged worldwide to operationalize the MEASURED trial.
- **Preventing Disease Progression:** Development of the MSTIR (**M**ovember-**SA**iGENCI **T**ransformational **I**ntegrated **R**epository) database underway, to identify biomarker-informed treatment strategies that prevent high-risk prostate cancer from advancing to fatal disease. Engaging with international research teams to conduct targeted research using MSTIR to accelerate the discovery of progression-prevention strategies.

Conclusions

Movember's prostate cancer portfolio demonstrates measurable research and clinical outcomes across equity, survivorship, clinical quality and research initiatives. These investments provide the foundation for scalable, evidence-informed improvements in prostate cancer survival and quality of life globally.

Funding Acknowledgements

This work is funded by Movember with additional support from governmental, community, and institutional partners.

Conflicts of Interest Disclosure Statement

The authors declare no conflicts of interest.